Identification
NameSparsomycin
Accession NumberDB04222  (EXPT02949)
TypeSmall Molecule
GroupsExperimental
Description

An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

Structure
Thumb
SynonymsNot Available
External IDs NSC-59729 / U-19183
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII6C940P63E7
CAS numberNot Available
WeightAverage: 361.437
Monoisotopic: 361.076612113
Chemical FormulaC13H19N3O5S2
InChI KeyXKLZIVIOZDNKEQ-CLQLPEFOSA-N
InChI
InChI=1S/C13H19N3O5S2/c1-8-10(12(19)16-13(20)14-8)3-4-11(18)15-9(5-17)6-23(21)7-22-2/h3-4,9,17H,5-7H2,1-2H3,(H,15,18)(H2,14,16,19,20)/b4-3+/t9-,23+/m0/s1
IUPAC Name
(2E)-N-[(2S)-1-hydroxy-3-[(R)-(methylsulfanyl)methanesulfinyl]propan-2-yl]-3-(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)prop-2-enamide
SMILES
CSC[[email protected]](=O)C[[email protected]](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sparsomycin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparsomycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sparsomycin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sparsomycin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Sparsomycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Sparsomycin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Sparsomycin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparsomycin.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sparsomycin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Henricus C. J. Ottenheijm, "Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds." U.S. Patent US4820712, issued April, 1986.

US4820712
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility1.59 mg/mLALOGPS
logP-1.3ALOGPS
logP-2.5ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)1.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.6 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.67 m3·mol-1ChemAxon
Polarizability35.53 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8944
Blood Brain Barrier-0.8279
Caco-2 permeable-0.6471
P-glycoprotein substrateSubstrate0.5232
P-glycoprotein inhibitor INon-inhibitor0.8592
P-glycoprotein inhibitor IINon-inhibitor0.9974
Renal organic cation transporterNon-inhibitor0.9232
CYP450 2C9 substrateNon-substrate0.7127
CYP450 2D6 substrateNon-substrate0.8125
CYP450 3A4 substrateSubstrate0.5161
CYP450 1A2 substrateNon-inhibitor0.7752
CYP450 2C9 inhibitorNon-inhibitor0.8087
CYP450 2D6 inhibitorNon-inhibitor0.8899
CYP450 2C19 inhibitorNon-inhibitor0.7924
CYP450 3A4 inhibitorNon-inhibitor0.6771
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9919
Ames testNon AMES toxic0.623
CarcinogenicityNon-carcinogens0.8003
BiodegradationNot ready biodegradable0.7831
Rat acute toxicity2.5203 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8591
hERG inhibition (predictor II)Non-inhibitor0.8647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassDiazines
Direct ParentPyrimidones
Alternative ParentsHydropyrimidines / Vinylogous amides / Heteroaromatic compounds / Ureas / Sulfoxides / Secondary carboxylic acid amides / Lactams / Sulfinyl compounds / Sulfenyl compounds / Azacyclic compounds
SubstituentsPyrimidone / Hydropyrimidine / Vinylogous amide / Heteroaromatic compound / Carboxamide group / Lactam / Secondary carboxylic acid amide / Sulfoxide / Urea / Sulfenyl compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 11:14